Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
View Patent ↗Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
1. A method for treating and assessing response to treatment with a long-acting topoisomerase-I inhibitor selected from SN-38 and irinotecan in a subject having metastatic breast cancer, the method comprising:
(i) determining the level of a tumor marker in a bodily fluid sample of the subject selected from blood, plasma, and serum to provide a reference level of the tumor marker, where the tumor marker is CA27.29;
(ii) treating said subject over a duration of time of at least 2 weeks by administering a dosage amount of the long-acting topoisomerase-I inhibitor on a given dosing schedule, wherein the long-acting topoisomerase-I inhibitor is pentaerythritolyl-4-arm-(polyethyleneglycol-1-methylene-2 oxo-vinylamino acetate-linked irinotecan), or a pharmaceutically acceptable salt thereof,
or has a structure:
or a pharmaceutically acceptable salt thereof;
(iii) determining the level of the tumor marker in a bodily fluid sample obtained from the subject following treatment of the subject according to step (ii), and within 6 weeks following initial administration of the long-acting topoisomerase-I inhibitor, wherein the bodily fluid is the same as in step (i); and
(iv) correlating the level of the tumor marker in step (iii) with response of the metastatic breast cancer to treatment with the long-acting topoisomerase-I inhibitor, wherein, in the event of a level of the tumor marker in step (iii) that is either unchanged or reduced from the reference level in step (i), a positive response to treatment is determined, and, in the event of a level of the tumor marker in step (iii) that is increased from the reference level in step (i), a negative response to treatment is determined;
where, in the event of determining a negative response to treatment in step (iv), either the dosage amount or dosing schedule in step (ii), or both, are altered.
2. The method of claim 1 , wherein in step (i), the level of the tumor marker is determined prior to treatment with the long-acting topoisomerase-I inhibitor.
3. The method of claim 1 , wherein the bodily fluid sample in steps (i) and (iii) is serum.
4. The method of claim 1 , wherein the reference level of the tumor marker in step (i) is elevated over normal baseline levels.
5. The method of claim 4 , wherein the tumor marker is CA27.29 and the reference level of CA27.29 is greater than 38 U/ml.
6. The method of claim 1 , wherein the duration of treatment is at least 3 weeks.
7. The method of claim 6 , wherein the duration of treatment is at least 6 weeks.
8. The method of claim 7 , wherein the duration of treatment is at least 12 weeks.
9. The method of claim 1 , wherein the level of the tumor marker is determined by an immunoassay.
10. The method of claim 1 , wherein a reduction in the level of the tumor marker of at least 25% by week 6 shows a positive correlation with progression-free survival in the subject of at least 4 months.
11. The method of claim 1 , wherein step (iii) is optionally repeated, either following additional treatment with the long-acting topoisomerase inhibitor I or following the cessation of treatment.
12. The method of claim 1 , wherein the subject has failed to respond to prior taxane-based treatment for the metastatic breast cancer.
13. The method of claim 1 , wherein the long-acting topoisomerase-I inhibitor is pentaerythritolyl-4-arm-(polyethyleneglycol-1-methylene-2 oxo-vinylamino acetate-linked-irinotecan), or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , wherein step (ii), the long-acting topoisomerase-I inhibitor is administered every 14 days.
15. The method of claim 13 , wherein step (ii), the long-acting topoisomerase-I inhibitor is administered every 21 days.
16. The method of claim 13 , wherein a reduction in the level of CA27.29 of greater than or equal to 25% at week 6 is indicative of a median progression free survival of the subject of 12 months.
17. The method of claim 13 , wherein the exposure of the metastatic breast cancer to SN-38 resulting from the treating step correlates with the level of CA27.29 in the subject and efficacy of the treatment.